Imricor Medical Systems (ASX:IMR) said the human factors study covering all of its devices currently under review by the US Food and Drug Administration has been completed, according to a Thursday Australian bourse filing.
The study is a critical step in the US FDA approval process, ensuring that each device can be used safely and effectively by clinicians in real-world settings, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.